Biotech Values

[genisi]

ILMN reports a restructuring

Given the uncertainties associated with academic and government research funding and the global economic environment, the company is implementing a restructuring to better align the company’s organization and cost structure. As a result, the company expects to record a restructuring charge of approximately $15-17 million, the majority of which will be recorded during the fourth quarter of 2011

http://finance.yahoo.com/news/Illumina-Reports-Financial-bw-3462350602.html?x=0&.v=1